Signal active
Bio
Jason Rhodes is a partner and focuses on the creation, development, and business strategy of novel therapeutics companies.
Jason is on the board of Replimune, Bicycle Therapeutics, and Raze Therapeutics. Prior to joining Atlas Venture in 2014, Jason was president and chief financial officer of Epizyme (NASDAQ: EPZM). Jason joined Epizyme when it was a private, research-stage company and was instrumental in charting the company’s strategic course and building the business, leading to Epizyme’s successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, and Eisai, raising more than $180 million in non-equity funding while retaining U.S. product rights.
Prior to Epizyme, Jason was vice president of business development at Alnylam (NASDAQ: ALNY), where he led corporate partnerships with companies including Takeda, GSK, Isis, Cubist, Roche, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Together, these partnerships brought in more than $200 million in non-equity funding.
Before joining Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH).
Earlier in his career, Jason worked on new business entrance, product strategy, and commercialization projects with biopharma and high tech companies.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the Berklee College of Music Presidential Advisory Council and spends his free time running, mountain biking with his kids, and loudly watching Spanish fútbol.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
1980
602
167
185
11-50
Venture Capital, Biotechnology, Health Care, Pharmaceutical
Jobs history
6
AAVantgarde Bio
Board Member
Invalid date - Current
Third Harmonic Bio
Board Member
Invalid date - Current
Raze Therapeutics
Chief Executive Officer
Invalid date - Current
K36 Therapeutics
Board of Directors
2021 - Current
Rectify Pharmaceuticals
Board Member
2021 - Current
Atlas Venture
Partner
2014 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Jason Rhodes is the Partner at Atlas Venture, based in United States, North America. With a background in Venture Capital, Jason Rhodes has a rich history of leadership and innovation. Jason Rhodes studied BA unknown @ Yale University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
17
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Apr 14, 2022 | Be Biopharma | Series B - Be Biopharma | Atlas Venture | 130.0M |
Jun 06, 2023 | AAVantgarde Bio | Series A - AAVantgarde Bio | Atlas Venture | 65.3M |
Jun 28, 2023 | K36 Therapeutics | Series B - K36 Therapeutics | Atlas Venture | 70.0M |
Jan 23, 2024 | - | Series C - Accent Therapeutics | Atlas Venture | 75.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.